Jianmin Yang

Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial

Yuankai Shi, Hang Su, Yongping Song et al. · The Lancet Haematology · 2019 · 233 citations

Lymphoid Neoplasia, Medicine, Immunotherapy +2

Fluidic Multivalent Membrane Nanointerface Enables Synergetic Enrichment of Circulating Tumor Cells with High Efficiency and Viability

Lingling Wu, Hong‐Ming Ding, Xin Qu et al. · Journal of the American Chemical Society · 2020 · 164 citations

Nanotherapeutics, Biomimetic Materials, Engineering +17

Point Mutation of the Proteasome β5 Subunit Gene Is an Important Mechanism of Bortezomib Resistance in Bortezomib-Selected Variants of Jurkat T Cell Lymphoblastic Lymphoma/Leukemia Line

Shuqing Lü, Jianmin Yang, Xianmin Song et al. · Journal of Pharmacology and Experimental Therapeutics · 2008 · 106 citations

Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line

Shuqing Lü, Zhilong Chen, Jianmin Yang et al. · Experimental Hematology · 2008 · 89 citations

Hematological Malignancy, T-lymphoblastic Lymphoma/leukemia Cells, Mixed-phenotype Acute Leukemia +9

Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line

Shuqing Lü, Jianmin Yang, Zhilong Chen et al. · Experimental Hematology · 2009 · 83 citations

Hematological Malignancy, Mixed-phenotype Acute Leukemia, Jurkat Cell Line +8